Early drug developers gather to discuss maximising drug investments, toxicology, safety and biomarkers.
This summit addresses the strategies and tools to fully optimise the early drug development trajectory in order to bring safe, effective and commercially viable drugs to market faster whilst achieving regulatory approval.
Key learning outcomes this year include:
Call for Papers
If you would like to be involved as a speaker or help shape the programme, please contact:
Tel: +44 (0) 207 202 7586